Aspen Pharmacare, South Africa’s largest drugmaker, has reached a €25 million settlement to resolve a dispute over an mRNA vaccine production contract with a European pharmaceutical partner, the company confirmed on Thursday. The agreement brings closure to months of negotiations surrounding the stalled COVID-19 vaccine fill-and-finish operations at its Gqeberha facility.
According to Reuters, the dispute stemmed from unmet production and supply obligations after vaccine demand in Africa dropped sharply in 2023, forcing Aspen to scale down its manufacturing capacity. The company had earlier partnered with Johnson & Johnson and later sought to pivot toward producing mRNA vaccines locally to boost regional pharmaceutical independence.
Aspen’s Chief Executive Officer, Stephen Saad, described the settlement as “a pragmatic resolution that allows the company to refocus on its core business and long-term vaccine strategy.” He emphasized that Aspen remains committed to expanding its vaccine manufacturing footprint in Africa through collaborations with global partners.
As reported by Bloomberg, the resolution is expected to improve Aspen’s cash flow position and restore investor confidence after months of legal uncertainty. Industry analysts noted that the settlement underscores the challenges African manufacturers face in balancing global vaccine supply dynamics with regional production goals.
